Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials | Zendy

Yuanyuan Jiao | Zendy; Bartolomé Moyá | Zendy; Mong-Jen Chen | Zendy; Alexandre Prehn Zavascki | Zendy; Hsin-Yin Tsai | Zendy; Xun Tao | Zendy; Dhruvitkumar S. Sutaria | Zendy; Arnold Louie | Zendy; John D. Boyce | Zendy; Deanna Deveson Lucas | Zendy; Tae Hwan Kim | Zendy; Brian T. Tsuji | Zendy; Robert A. Bonomo | Zendy; George L. Drusano | Zendy; Jürgen B. Bulitta | Zendy

Open Access

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

Author(s) -

Yuanyuan Jiao,

Bartolomé Moyá,

Mong-Jen Chen,

Alexandre Prehn Zavascki,

Hsin-Yin Tsai,

Xun Tao,

Dhruvitkumar S. Sutaria,

Arnold Louie,

John D. Boyce,

Deanna Deveson Lucas,

Tae Hwan Kim,

Brian T. Tsuji,

Robert A. Bonomo,

George L. Drusano,

Jürgen B. Bulitta

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00425-19

Subject(s) - aminoglycoside , lactam , gram negative bacteria , medicine , gram , randomized controlled trial , antibiotics , combination therapy , microbiology and biotechnology , bacteria , pharmacology , biology , chemistry , stereochemistry , biochemistry , genetics , escherichia coli , gene

There is a great need for efficacious therapies against Gram-negative bacteria. Double β-lactam combination(s) (DBL) are relatively safe, and preclinical data are promising; however, their clinical role has not been well defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research